Commitment to Patient Access and Affordability of Our Medicines
We recognize that too many patients in the United States are struggling to afford their medications. Our commitment to transparency as part of our Pricing Principles extends beyond responsible launch pricing and limited price increases, and therefore we offer a suite of programs to address a range of patient needs.
We feel a special obligation to address pressing issues around access to, and affordability of, insulin. In order to help address the needs of patients, Sanofi was the first company to introduce a program in which uninsured patients could access insulin for a single, low monthly cost. With our Insulins Valyou Savings Program, introduced in 2018 and expanded in April 2019, all uninsured patients, regardless of income level, can access one or multiple Sanofi insulins, including Lantus® (insulin glargine injection) 100 Units/mL, Toujeo® (insulin glargine injection) 300 Units/mL, Admelog® (insulin lispro injection) 100 Units/mL and Apidra® (insulin glulisine injection) 100 Units/mL, for a fixed price of $99 per month for up to 10 boxes of pens and/or 10 mL vials.
Additionally, our copay assistance programs for commercially insured patients, regardless of income level, limit out-of-pocket expenses for a majority of participating patients to $0 or $10. Through Sanofi Patient Connection, we provide free medications to eligible patients with a demonstrated financial need.
If you are having trouble accessing or affording your medicines, visit Sanofi Patient Connection to learn about resources or programs that may be available to you. Sanofi has live support specialists at (855) 984-6302 to answer your questions and help navigate your individual situation in an effort to find the best resources and programs to help lower your out-of-pocket costs.